Search Result

Results for "

pathophysiologies

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CGRP Receptor (1) Endogenous Metabolite (2) Ferroptosis (1) HDAC (1) Leukotriene Receptor (1) P2X Receptor (1)
By Research Areas:	Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D1412

LPd peroxida probe 1 Publications Verification	Ferroptosis	Others
LPd peroxida probe, a marker of ferroptosis, is a useful fluorescent probe for investigating the roles of lipid peroxidation in a variety of cell pathophysiologies. LPd peroxida probe reduces lipid hydroperoxides to lipid alcohols and is used for imaging lipid hydroperoxides in living cells .

HY-W009390

DL-Homocystine	Endogenous Metabolite	Metabolic Disease
DL-Homocystine is the double-bonded form of homocysteine and homocysteine is recognized as an important substance in the pathogenesis and pathophysiology of schizophrenia.

HY-134992

Vazegepant Zavegepant; BHV-3500	CGRP Receptor	Neurological Disease
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology .

HY-W009390S

DL-Homocystine-3,3,3’,3’,4,4,4’,4’-d8	Endogenous Metabolite	Metabolic Disease
DL-Homocystine-3,3,3’,3’,4,4,4’,4’-d₈ is the deuterium labeled DL-Homocystine. DL-Homocystine is the double-bonded form of homocysteine and homocysteine is recognized as an important substance in the pathogenesis and pathophysiology of schizophrenia[1][2].

HY-101418

JNJ-47965567 3 Publications Verification	P2X Receptor	Neurological Disease
JNJ-47965567 is a centrally permeable, high-affinity, selective P2X7 antagonist, with pK_is of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology .

HY-162027

PB118	HDAC	Neurological Disease
PB118 is a potent inhibitor of HDAC6 that plays an important role in the pathophysiology of Alzheimer's disease .

HY-139112

Leukotriene B4 dimethyl amide	Leukotriene Receptor	Inflammation/Immunology
Leukotriene B4 dimethyl amide, an immunomodulator, stimulates contraction of isolated guinea pig lung entities. Leukotriene B4 (LTB(4)) also stimulates human neutrophil migration, and LTB(4) antagonists may have anti-inflammatory activity in inflammatory pathophysiology .

HY-100740A

Lanabecestat hydrochloride AZD-3293 hydrochloride; LY3314814 hydrochloride	Others	Neurological Disease
Lanabecestat (AZD-3293) hydrochloride is a potent BACE1 inhibitor that has been investigated for its potential as a modifying treatment for Alzheimer's disease. Lanabecestat (hydrochloride) demonstrated significant dose- and time-dependent reductions in concentrations of amyloid beta peptides in plasma, cerebrospinal fluid, and brain. Lanabecestat (hydrochloride) was also shown to produce reductions in Aβ neuritic plaque burden without demonstrating clinical benefits or slowing the progression of Alzheimer's disease pathophysiology.

Cat. No.	Product Name

HY-L086

Neurodegenerative Disease-related Compound Library	2,609 compounds
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour. MCE offers a unique collection of 2,609 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Neurodegenerative Disease-related Compound Library

2,609 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2,609 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Type